Form 8-K · Current Report · Filed 2026-02-17
Danaher Announces Acquisition of Masimo Corporation
On February 17, 2026, Danaher Corporation announced its entry into an Agreement and Plan of Merger with Masimo Corporation, a leading specialty diagnostics provider.
- Filer
- Danaher Corporation DHR · NYSE
- Filed
- Accession
- 0001193125-26-053124
- CIK
- 0000313616
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
Danaher will acquire all outstanding shares of Masimo's common stock for $180 per share in cash, representing a total enterprise value of approximately $9.9 billion. The transaction is expected to close in the second half of 2026 and is subject to customary conditions, including regulatory clearances and Masimo shareholder approval.
Items reported
Reported Item
Market reaction
Close before filing
$212.58
Next session
-1.9%
Since filing
-8.3%
Latest close
$194.98
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DHR reporting the same item, with the next session's move:
About Danaher Corporation
Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.
Never miss another DHR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.